G

Grace Research, LLC | Shreveport, LA

Research site

(Unclaimed)

Location

1811 East Bert Kouns, Suite 100, Shreveport, Louisiana, United States of America

Site insights

Top conditions

Top treatments

Empagliflozin

TQJ230

Pelacarsen

BI 456906

Ezetimibe

Survodutide

BI 690517

Triglyceride

Obicetrapib

Bococizumab

Parent organization

This site is a part of Grace Research, LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 17 total trials

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left...

Enrolling

Heart Failure

Drug: empagliflozin

Drug: placebo

Locations recently updated

ACP-204 in Adults With Alzheimer's Disease Psychosis

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...

Enrolling

Alzheimer's Disease Psychosis

Drug: Placebo

Drug: ACP-204

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blin...

Enrolling

Cardiovascular Disease and Lipoprotein(a)

Drug: Pelacarsen (TQJ230)

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Placebo

Drug: Inclisiran sodium 300 mg